Table 6.
Effect of LN18178 supplementation on serum metabolic markers of the study participants
| Variable | Evaluation days | Placebo | LN18178-200 | LN18178-400 |
|---|---|---|---|---|
| Creatinine (μmol/L) | Baseline | 77.79 ± 10.17 | 82.21 ± 12.02 | 77.79 ± 13.26 |
| Day 56 | 76.02 ± 12.55 | 83.98 ± 14.14 (0.110*; 0.099#) | 78.67 ± 14.76 (0.5808*; 0.4686#) | |
| BUN (mg/dL) | Baseline | 9.91 ± 2.96 | 9.69 ± 2.68 | 9.38 ± 2.44 |
| Day 56 | 9.86 ± 2.93 | 9.09 ± 1.98 (0.181*; 0.3804#) | 10.54 ± 2.48 (0.006*; 0.136#) | |
| AST (U/L) | Baseline | 24.13 ± 8.30 | 21.97 ± 5.75 | 22.48 ± 6.40 |
| Day 56 | 25.16 ± 10.26 | 23.20 ± 5.85 (0.3661*; 0.3156#) | 23.64 ± 6.23 (0.4977*; 0.4287#) | |
| ALT (U/L) | Baseline | 27.53 ± 13.20 | 23.38 ± 12.30 | 23.65± 8.89 |
| Day 56 | 29.70 ± 15.77 | 24.05 ± 12.35 (0.8164*; 0.0888#) | 25.54 ± 13.30 (0.4507*; 0.2108#) | |
| ALP (U/L) | Baseline | 86.89±17.90 | 84.70 ± 20.87 | 86.23 ± 19.88 |
| Day 56 | 85.21 ± 20.23 | 83.84 ± 20.81 (0.8588*; 0.7729#) | 84.65 ± 19.79 (0.6508; 0.9019#) |
Data present as mean ± SD. Placebo (n=38), LN18178-200 (n=37), and LN18178-400 (n=40). ALP, alkaline phosphatase, ALT, alanine Transaminase; AST, aspartate aminotransferase, BUN, blood urea nitrogen. In parentheses, * and # indicate P-values in intragroup comparison (vs. baseline) using student t-test and in intergroup comparison (vs. placebo) analyzed using ANCOVA, respectively. The changes are not significant.